Aribio Receives $10 Million Upfront Payment from China’s Fuxing Pharmaceutical Under Contract
10 Days After AR1001 Technology Export Agreement
"Remaining $50 Million Upfront Payment to Be Made in June"
Aribio announced on May 26 that it has received 10 million dollars (approximately 15.1 billion won) out of the 60 million dollars (about 90.6 billion won) upfront payment as part of its global exclusive sales agreement for AR1001 with Chinese pharmaceutical company Fuxing Pharmaceutical.
The total value of this contract is approximately 4.7 billion dollars (about 7.1 trillion won). Aribio explained that foreign currency funds were actually received just about 10 days after the contract announcement.
The company stated that, considering it usually takes several months to remit overseas technology fees due to the approval procedures of the State Administration of Foreign Exchange (SAFE) in China, the execution was relatively fast.
According to the company, Fuxing Pharmaceutical is also in the process of arranging payment procedures for the remaining 50 million dollars (about 75.5 billion won) of the upfront payment within June.
AR1001 is an oral Alzheimer's disease treatment candidate. A global Phase 3 clinical trial, named 'POLARIS-AD', is currently underway. The trial, targeting approximately 1,500 patients across 13 countries, is in its final stages.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Aribio explained that about 95% of all patients are participating in the extension study and that long-term dosing data is also being accumulated.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.